10 Oct 2011
Lady Alison Myners speaks at Bircham Dyson Bell LLP Ladies Networking Evening
Lady Alison Myners, chair of the The Institute of Contemporary Art (ICA) and a leading light in the contemporary art world attended Bircham Dyson Bell LLPs ladies networking event to talk about her life working with charitable organisations and how to raise money and ensure proper governance.
23 Oct 2009
Bircham Dyson Bell acts on £54.5 million Recommended Cash Offer for Celsis
Bircham Dyson Bell has acted for North Atlantic Value LLP (NAV) and Nastor Investments Limited on the £54.5 million recommended cash offer by Nastor Investments Limited for the entire issued share capital of Celsis International Plc, a company listed on the Official List of the UKLA. Celsis is a leading supplier of innovative life science products and laboratory services to the global pharmaceutical and consumer products industries, with a well regarded brand and strong sector expertise.
06 Aug 2009
Immupharma
The Corporate team at Bircham Dyson Bell congratulates the drug discovery company and longstanding client ImmuPharma plc for their success at the European Medi-Sciences Awards Dinner 2009. ImmuPharma's award is for Breakthrough of the Year 2009 in recognition of its licensing deal with Cephalon Inc for the development and commercialisation of its lead compound Lupuzor under which it has so far received $45m. This product has the potential to be novel therapy for the treatment of Lupus, a chronic autoimmune, inflammatory disease.
31 Jul 2009
Corporate Group at Bircham Dyson Bell scoops industry award
Top 100 law firm Bircham Dyson Bell (BDB) has received another industry award. The firm’s Corporate Group has been voted the Listed Company Law Advisor of The Year (UK) in the 2009 ACQCountry awards by ACQ Finance magazine.
John Turnbull, Partner and Head of the Corporate Group said:
17 Jul 2009
Bircham Dyson Bell LLP acts for Volvere plc
Bircham Dyson Bell LLP acted for Volvere plc (the AIM traded turnaround investment company) on its disposal of Sira Certification Service, Sira Test and Certification Limited, Sira Consulting Limited and Sira Environmental Limited (together "Sira Certification") to CSA Certification (UK) Ltd, a wholly-owned subsidiary of the Canadian-based CSA Group ("CSA") for up to £8.6 million in cash. The sale completed on 7th July 2009.
21 Apr 2009
3D Diagnostic Imaging Plc (3D) successful admission to the PLUS-quoted market
Bircham Dyson Bell acted for 3D Diagnostic Imaging Plc (3D) on its successful admission to the PLUS-quoted market with a market capitalisation of £7 million.
21 Apr 2009
Bircham Dyson Bell acts on take private of GNE Group PLC
Bircham Dyson Bell acted for Norcliffe Investments Limited, a bid vehicle established by North Atlantic Smaller Companies Investment Trust PLC and Martyn Radcliffe, in connection with its cash offer for GNE Group PLC, valuing GNE at £26.4 million. The offer was made after proposals put forward by NASCIT and Martyn Ratcliffe and agreed with the board of GNE encountered resistance from a group of minority shareholders.
Head of Corporate, John Turnbull, who led the team acting on the transaction commented:
09 Apr 2009
Bircham Dyson Bell acts for ValiRx Plc
Bircham Dyson Bell acted for AIM company ValiRx Plc on its recent placing. The Company raised £580k, which will be used by the company to accelerate the regulatory approval process for the launch of its Human Papilloma Virus (“HPV”) diagnostic test kit for cervical cancer and to progress its therapeutic products through to first in man clinical trials.
For further information please contact Andrew Chadwick
20 Feb 2009
Bircham Dyson Bell acts for Awabi Plc
Bircham Dyson Bell acted for Awabi Plc on its reverse takeover of CarbonDesk Limited and the readmission of the renamed CarbonDesk Group Plc to trading on the PLUS market. The Company also completed a fundraising through a placing of new shares and conversion of loan stock. CarbonDesk is an independent emissions broker offering clients specialist independent advice, execution and research.
For further information please contact Andrew Chadwick